Skip to content

Author

D. Polatova

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Viral exploitation of p300/CBP at the virus-cancer interface: Chromatin regulation, oncogenesis, immune evasion, and therapeutic targeting.

The transcriptional coactivators p300 and CREB-binding protein (CBP) integrate chromatin remodeling, enhancer activity, lysine acetylation, immune signaling, and tumor-suppressor control, making them recurrent targets of viral proteins. This narrative review examines p300/CBP at the virus-cancer interface, prioritizing...

A. Atoom, J. Rizaev, D. Polatova et al. · 0 citations
Review Open access Sep 2026

Oncolytic virotherapy at the tumor microenvironment-CAR Therapy interface: Mechanisms, clinical translation, and future directions.

Oncolytic virotherapy has evolved from a tumor-selective cytolytic strategy into a programmable immunotherapeutic platform that reshapes the tumor microenvironment (TME). Oncolytic viruses (OVs) selectively infect malignant cells, induce immunogenic cell death, release tumor antigens, and activate innate and adaptive i...

A. Atoom, J. Rizaev, D. Polatova et al. · 0 citations
Review Open access Sep 2026

Oncostatin M as a Multifunctional Regulator of Breast Cancer Progression: Current Insights and Future Therapeutic Avenues

Breast cancer (BC) constitutes the most prevalent malignancy globally, with an incidence of approximately 80%–85% for invasive ductal carcinoma (IDC) and 10%–15% for invasive lobular carcinoma (ILC), and a persistently high mortality and morbidity rate. Although IDC and ILC originate from distinct cellular lineages (du...

Muslem Nuseir, Farrukh Ismatov, A. Abdulqader et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.